General Information of Drug Transporter (DT)
DT ID DTD0248 Transporter Info
Gene Name SLC29A2
Transporter Name Equilibrative nucleoside transporter 2
Gene ID
3177
UniProt ID
Q14542
Post-Translational Modification of This DT
Overview of SLC29A2 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-N-glycosylation X-Phosphorylation X-Ubiquitination X: Amino Acid

N-glycosylation

  Asparagine

          3 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC29A2 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

48

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC29A2 Asparagine 48 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC29A2 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

57

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC29A2 Asparagine 57 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC29A2 [2]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

225

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC29A2 Asparagine 225 has the potential to affect its expression or activity.

Phosphorylation

  Serine

          7 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC29A2 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

49

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 49 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC29A2 [4] , [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

244

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 244 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC29A2 [6] , [7]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

251

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 251 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC29A2 [8] , [9]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

252

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 252 has the potential to affect its expression or activity.

  PTM Phenomenon 5

Have the potential to influence SLC29A2 [10]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

346

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 346 has the potential to affect its expression or activity.

  PTM Phenomenon 6

Have the potential to influence SLC29A2 [10]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

349

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 349 has the potential to affect its expression or activity.

  PTM Phenomenon 7

Have the potential to influence SLC29A2 [10]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

358

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Serine 358 has the potential to affect its expression or activity.

  Threonine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC29A2 [3]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

50

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Threonine 50 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC29A2 [10]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

348

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Threonine 348 has the potential to affect its expression or activity.

  Tyrosine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC29A2 [10] , [11]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

350

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC29A2 Tyrosine 350 has the potential to affect its expression or activity.

Ubiquitination

  Lysine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC29A2 [12]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

226

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC29A2 Lysine 226 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC29A2 [12]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

238

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC29A2 Lysine 238 has the potential to affect its expression or activity.
References
1 Functional analysis of site-directed glycosylation mutants of the human equilibrative nucleoside transporter-2. Arch Biochem Biophys. 2003 Mar 1;411(1):19-26.
2 dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: S29A2_HUMAN)
3 Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res. 2013 Jun 7;12(6):2414-21.
4 Comparative phosphoproteomic analysis reveals signaling networks regulating monopolar and bipolar cytokinesis. Sci Rep. 2018 Feb 2;8(1):2269.
5 Large-Scale Reanalysis of Publicly Available HeLa Cell Proteomics Data in the Context of the Human Proteome Project. J Proteome Res. 2018 Dec 7;17(12):4160-4170.
6 Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 2018 Dec 14;37(24):e99559.
7 Modulation of Cl- signaling and ion transport by recruitment of kinases and phosphatases mediated by the regulatory protein IRBIT. Sci Signal. 2018 Oct 30;11(554):eaat5018.
8 Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Large-Scale Phosphoproteomics with the Production of over 11,000 Phosphopeptides from the Colon Carcinoma HCT116 Cell Line. Anal Chem. 2019 Feb 5;91(3):2201-2208.
9 UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515.
10 An Augmented Multiple-Protease-Based Human Phosphopeptide Atlas. Cell Rep. 2015 Jun 23;11(11):1834-43.
11 An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62.
12 Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.